MedTrace Logo

Clinical Study for the Evaluation of Safety and Tolerability of NCP112 Eye Drops

NCT06263998 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-10-01

No results posted yet for this study

Summary

The objective is to evaluate the safety, local tolerability, and pharmacokinetics of NCP112 eye drops through single and multiple dose-escalation ocular administrations in healthy adults.

Conditions

  • Xerophthalmia

Interventions

DRUG

NCP112

NCP112 topical ophthalmic solution

DRUG

NCP112 Placebo

Placebo comparator

Sponsors & Collaborators

  • Huons Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • INJIN JANG, M.D.,Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-11
Primary Completion
2025-11-28
Completion
2026-01-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06263998 on ClinicalTrials.gov